The new guidelines offer conditional recommendations for the long-term use of specific GLP-1 therapies—namely liraglutide, semaglutide, and tirzepatide—in treating adults with obesity (defined as a Body Mass Index, or BMI, of 30 or higher). Representational image

The World Health Organization (WHO) has released its first-ever global guidelines on the use of Glucagon-Like Peptide-1 (GLP-1) receptor agonist therapies, acknowledging the drugs’ crucial role in addressing the escalating global obesity epidemic. This landmark guidance comes as the consumption of these medications, including blockbuster brands like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), has soared worldwide for weight management.

The WHO’s recommendations frame obesity as a complex, chronic, and relapsing d

See Full Page